The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

Mar. 05, 2018
Applicants:

The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center), Rishon-LeZion, IL;

Mor Research Applications Ltd., Tel-Aviv, IL;

Inventors:

Hinanit Koltai, Rishon-LeZion, IL;

Yoram Kapulnik, Karmey Yosef, IL;

Dvora Namdar, Beit Gamliel, IL;

Moran Mazuz, Rishon-LeZion, IL;

Ido Laish, Kiryat-Ono, IL;

Timna Naftali, Tel-Aviv, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/353 (2006.01); A61K 31/05 (2006.01); A61K 31/015 (2006.01); A61K 31/01 (2006.01); A61K 31/194 (2006.01); A61K 31/045 (2006.01); A61K 31/12 (2006.01); A61P 1/00 (2006.01); A61P 29/00 (2006.01); A61K 31/352 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/353 (2013.01); A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/194 (2013.01); A61K 31/352 (2013.01); A61K 36/185 (2013.01); A61P 1/00 (2018.01); A61P 29/00 (2018.01); A61K 45/06 (2013.01);
Abstract

A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.


Find Patent Forward Citations

Loading…